Key Highlights
- Oxford Biomedica plc (LSE:OXB) shares rose 3.57% on Wednesday, 30 September 2026.
- Interim Revenue increased 10% at constant currency to £80.2 million for the six months to 30 June 2026.
- The revenue Backlog stood at about £193 million, with £168 million of forecast 2026 revenue covered by contracted orders.
- FY2026 revenue guidance of £180 million to £200 million and 2027 growth guidance of 25% to 30% were reiterated.
- Vice chair Peter Soelkner bought shares on several occasions in late September, signalling board confidence.
Recovery Gathers Pace
Oxford Biomedica plc (LSE:OXB), the cell and gene therapy contract development and Manufacturing organisation, gained 3.57% on 30 September 2026. The move continued a recovery from a sharp sell-off at the start of September, when the shares dropped to the mid-430p range from above 520p.
Since the interim results on 22 September, the stock has stabilised around the 500p level. Director buying and reassurance that guidance remains intact have helped rebuild confidence.
Interim Results: Growth and Visibility
For the first half of 2026, OXB delivered constant currency revenue growth of 10% to £80.2 million, while reported revenue rose 9% to £79.8 million. Growth reflected continued Demand across manufacturing and development services.
Revenue visibility remains a key strength. The company reported a revenue backlog of around £193 million at 30 June, and approximately £168 million of forecast 2026 revenue was covered by contracted client orders as of September. That level of coverage supports confidence in second-half delivery.
Gross Margin narrowed to 37% from 43%, reflecting product mix and ramp-up costs at new capacity. Management reiterated expectations for a mid-single-digit EBITDA margin for 2026, excluding one-off costs.
The August Guidance Reset
In August, OXB lowered its 2026 revenue guidance to £180 million to £200 million. The company cited programme deferrals, delayed client timelines, a change in procurement approach at one larger client and a six-month delay in readying its Durham, North Carolina site.
Management also noted that some clients are moving to staged contracting, ordering individual work packages rather than full programmes. This can delay revenue recognition even when demand remains strong. The Durham site is now online for GMP manufacturing.
Record Client Wins
Despite the guidance change, commercial momentum has been strong. OXB signed 17 new clients in the first half of 2026, more than 30% above the total signed in the whole of 2025. That pipeline underpins the company's guidance for 25% to 30% revenue growth in 2027.
The longer-term ambition is to generate around £500 million of annual revenue by 2030, with EBITDA margins approaching 30% as scale and operational Leverage improve.
Director Buying Signals Confidence
Peter Soelkner, non-executive director and vice chair, bought shares on 24, 25 and 28 September 2026. While the amounts are modest, repeated purchases soon after results are often viewed as a signal that the board believes the shares are undervalued.
Why Investors Are Watching LSE:OXB
- Second-half delivery: hitting the £180 million to £200 million range is crucial to rebuilding trust.
- 2027 growth: guidance of 25% to 30% growth implies a strong acceleration.
- Durham ramp-up: the US site is key to serving North American clients.
- Client wins: record new Business supports long-term revenue ambitions.
- Margin progress: investors want evidence of improving EBITDA profitability.
Risks to Consider
Further client delays, slower biotech funding and execution risks around new capacity could affect results. The shares have been volatile, with a 52-week range of 420p to 962p.
Outlook
The 3.57% rise in LSE:OXB reflects a market increasingly comfortable that the August guidance cut was a timing issue rather than a demand problem. With strong backlog coverage, record client wins and insider buying, Oxford Biomedica remains a key name in the UK healthcare sector heading into its important second-half delivery period.






Please wait processing your request...